Aquestive Therapeutics, Inc. (AQST) vs Shattuck Labs, Inc. (STTK)

A side-by-side comparison of Aquestive Therapeutics, Inc. and Shattuck Labs, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — AQST vs STTK

growth of $100 · dividends reinvested · last 6y
AQST -2.1% (-0.4%/yr)STTK -66.4% (-16.6%/yr)AQST compounded faster over this window
0100200300Start $100202120222023202420252026$98$34
AQST STTK

AQST vs STTK: by the numbers

  • •AQST is the larger company ($578M vs $530M market cap).
  • •Both run net losses; AQST's is the smaller (-144.63% vs -5256.80% net margin).
  • •Both shrank revenue over the past five years; AQST's decline was smaller (-0.58% vs -11.25% CAGR).

Metrics side by side

Valuation

MetricAQSTSTTK
P/S ratio10.69529.58
P/B ratioN/A2.51

Profitability

MetricAQSTSTTK
Gross margin67.04%-195.10%
Operating margin-156.36%-5150.80%
Net margin-144.63%-5256.80%
ROEN/A-24.90%
ROIC-45.62%-26.20%

Growth (annualized)

MetricAQSTSTTK
Revenue CAGR (5Y)-0.58%-11.25%
Total return CAGR (5Y)2.24%-20.11%

Frequently asked

Which has grown faster, AQST or STTK?
Neither grew: over the past five years both shrank revenue, with AQST's decline the smaller — AQST at a -0.58% CAGR versus STTK at -11.25%.
How have AQST and STTK total returns compared?
Over the past 5 years, AQST delivered 2.24% and STTK delivered -20.11% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.